$GCTK
GlucoTrack Inc

2023 Q4 Form 10-Q Financial Statement

#000149315223040961 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $675.0K $531.0K $495.0K
YoY Change -1.17% 7.27% 54.69%
% of Gross Profit
Research & Development $1.742M $1.693M $434.0K
YoY Change 188.41% 290.09% -2.91%
% of Gross Profit
Depreciation & Amortization -$8.000K $11.00K $5.000K
YoY Change -300.0% 120.0% -54.55%
% of Gross Profit
Operating Expenses $2.417M $2.224M $929.0K
YoY Change 87.8% 139.4% 21.12%
Operating Profit -$2.224M -$929.0K
YoY Change 139.4% 21.12%
Interest Expense $5.000K $1.000K $2.000K
YoY Change -61.54% -50.0% -77.78%
% of Operating Profit
Other Income/Expense, Net $0.00 -$1.000K
YoY Change -100.0% -97.83%
Pretax Income -$2.412M -$2.223M -$928.0K
YoY Change 87.41% 139.55% 15.42%
Income Tax
% Of Pretax Income
Net Earnings -$2.412M -$2.223M -$928.0K
YoY Change 87.41% 139.55% 15.42%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 -$0.06
Diluted Earnings Per Share -$0.11 -$0.10 -$0.06
COMMON SHARES
Basic Shares Outstanding 20.89M shares 20.89M shares 15.47M shares
Diluted Shares Outstanding 22.97M shares 15.47M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.492M $6.888M $3.241M
YoY Change 94.29% 112.53% -53.7%
Cash & Equivalents $4.492M $6.888M $3.241M
Short-Term Investments
Other Short-Term Assets $376.0K $281.0K $187.0K
YoY Change 461.19% 50.27% 187.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.868M $7.169M $3.428M
YoY Change 104.62% 109.13% -53.79%
LONG-TERM ASSETS
Property, Plant & Equipment $27.00K $17.00K $44.00K
YoY Change -32.5% -61.36% -67.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $9.000K $39.00K
YoY Change -47.37% -76.92% -50.0%
Total Long-Term Assets $37.00K $26.00K $83.00K
YoY Change -37.29% -68.67% -61.21%
TOTAL ASSETS
Total Short-Term Assets $4.868M $7.169M $3.428M
Total Long-Term Assets $37.00K $26.00K $83.00K
Total Assets $4.905M $7.195M $3.511M
YoY Change 101.19% 104.93% -54.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $839.0K $1.249M $713.0K
YoY Change 24.85% 75.18% 10.54%
Accrued Expenses $0.00
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.512M $1.454M $965.0K
YoY Change 49.26% 50.67% 7.46%
LONG-TERM LIABILITIES
Long-Term Debt $196.0K $184.0K $191.0K
YoY Change 0.51% -3.66% -4.98%
Other Long-Term Liabilities $196.0K $184.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $196.0K $184.0K $191.0K
YoY Change 0.51% -3.66% -18.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.512M $1.454M $965.0K
Total Long-Term Liabilities $196.0K $184.0K $191.0K
Total Liabilities $1.708M $1.638M $1.156M
YoY Change 41.39% 41.7% 2.12%
SHAREHOLDERS EQUITY
Retained Earnings -$109.9M -$107.4M -$100.6M
YoY Change 7.8% 6.79%
Common Stock $113.0M $113.0M $102.9M
YoY Change 9.58% 9.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.197M $5.557M $2.355M
YoY Change
Total Liabilities & Shareholders Equity $4.905M $7.195M $3.511M
YoY Change 101.19% 104.93% -54.0%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$2.412M -$2.223M -$928.0K
YoY Change 87.41% 139.55% 15.42%
Depreciation, Depletion And Amortization -$8.000K $11.00K $5.000K
YoY Change -300.0% 120.0% -54.55%
Cash From Operating Activities -$2.411M -$1.877M -$608.0K
YoY Change 156.49% 208.72% -31.99%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.411M -1.877M -608.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -2.411M -1.877M -608.0K
YoY Change 157.86% 208.72% -31.99%
FREE CASH FLOW
Cash From Operating Activities -$2.411M -$1.877M -$608.0K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$2.411M -$1.877M -$608.0K
YoY Change 157.31% 208.72% -31.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
GCTK Proceeds Received From Underwritten Public Offering
ProceedsReceivedFromUnderwrittenPublicOffering
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
GCTK Deemed Dividend Upon Trigger Of Down Round Protection
DeemedDividendUponTriggerOfDownRoundProtection
usd
CY2022Q3 GCTK Deemed Dividend Related To Trigger Of Down Round Protection Feature
DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
usd
GCTK Deemed Dividend Related To Trigger Of Down Round Protection Feature
DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001506983
CY2023Q3 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
usd
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
usd
GCTK Adjustments To Additional Paid In Capital Deemed Dividend Resulted From Trigger Of Down Round Protection Feature Of Certain Warrants Granted
AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q3 GCTK Deemed Dividend Related To Trigger Of Down Round Protection Feature
DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41141
dei Entity Registrant Name
EntityRegistrantName
GLUCOTRACK, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0668934
dei Entity Address Address Line1
EntityAddressAddressLine1
301 Route 17 North
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
dei Entity Address City Or Town
EntityAddressCityOrTown
Rutherford
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07070
dei City Area Code
CityAreaCode
(201)
dei Local Phone Number
LocalPhoneNumber
842-7715
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
GCTK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20892193 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6888000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2312000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
281000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
67000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
7169000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2379000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
9000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
19000 usd
CY2023Q3 us-gaap Assets
Assets
7195000 usd
CY2022Q4 us-gaap Assets
Assets
2438000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1249000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
672000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
205000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
341000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1454000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1013000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
184000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
195000 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
184000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
195000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1638000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1208000 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20892193 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20892193 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15500730 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15500730 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
20000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20892193 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20892193 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15500730 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15500730 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
20000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
112944000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
103095000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17000 usd
CY2022Q4 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
4000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107441000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101901000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5557000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1230000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7195000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2438000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1693000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
434000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2962000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1363000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
531000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
495000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1725000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1782000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2224000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
929000 usd
us-gaap Operating Expenses
OperatingExpenses
4687000 usd
us-gaap Operating Expenses
OperatingExpenses
3145000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2224000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-929000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4687000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3145000 usd
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1000 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1000 usd
CY2023Q3 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
1000 usd
CY2022Q3 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
2000 usd
GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
2000 usd
GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
-2000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2223000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-928000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4685000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3148000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
17000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
36000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2217000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-929000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4668000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3112000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22968663 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22968663 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15473521 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15473521 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20032634 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20032634 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15468279 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15468279 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1230000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4685000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8730000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
5000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
260000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5557000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7743000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2223000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
31000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5557000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5155000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3148000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
36000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
20000 usd
GCTK Stock To Be Issued During Period Value Restricted Stock Award Gross
StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
18000 usd
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
274000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2355000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3190000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3190000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-928000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000 usd
CY2022Q3 GCTK Stock To Be Issued During Period Value Restricted Stock Award Gross
StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
18000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
76000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2355000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2355000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4685000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3148000 usd
us-gaap Depreciation
Depreciation
21000 usd
us-gaap Depreciation
Depreciation
19000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
260000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
274000 usd
GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
5000 usd
GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
38000 usd
GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
4000 usd
GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
8000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
216000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
148000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
598000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
117000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-134000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
51000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4147000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2789000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000 usd
GCTK Proceeds Received From Underwritten Public Offering
ProceedsReceivedFromUnderwrittenPublicOffering
8730000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8730000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-17000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-40000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4566000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2833000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2331000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6113000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6897000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3280000 usd
GCTK Deemed Dividend Upon Trigger Of Down Round Protection
DeemedDividendUponTriggerOfDownRoundProtection
855000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107441000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
8730000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2223000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-928000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4685000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3148000 usd
GCTK Deemed Dividend Related To Trigger Of Down Round Protection Feature
DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
855000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2223000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2223000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
928000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
928000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5540000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5540000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3148000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
3148000 usd
CY2022Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
33456 shares
CY2023Q2 us-gaap Common Stock Call Or Exercise Features
CommonStockCallOrExerciseFeatures
the Company received gross proceeds of approximately $10 million for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of $1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of $0.001.
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10000000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1270000 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.36
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
855000 usd
CY2023Q2 us-gaap Share Price
SharePrice
1
CY2023Q2 us-gaap Share Price
SharePrice
1

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001493152-23-040961-index-headers.html Edgar Link pending
0001493152-23-040961-index.html Edgar Link pending
0001493152-23-040961.txt Edgar Link pending
0001493152-23-040961-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
gctk-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gctk-20230930_cal.xml Edgar Link unprocessable
gctk-20230930_def.xml Edgar Link unprocessable
gctk-20230930_lab.xml Edgar Link unprocessable
gctk-20230930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed